Your session is about to expire
← Back to Search
Durvalumab + Tremelimumab for Non-Small Cell Lung Cancer (MYSTIC Trial)
MYSTIC Trial Summary
This trial will study whether a combination of two immunotherapy drugs is more effective than standard chemotherapy in treating patients with a certain type of lung cancer.
MYSTIC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMYSTIC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 33 Patients • NCT03007407MYSTIC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung cancer is a mix of small-cell and non-small cell types.I am 18 years old or older.My cancer does not have EGFR mutations or ALK rearrangements.I haven't received any treatment for my recurrent or metastatic NSCLC.My brain or spinal metastases are stable and don't require steroids.I have or had an autoimmune or inflammatory disorder like Crohn's disease.My condition is Stage IV non-small cell lung cancer.I have previously received immunotherapy but not cancer vaccines.I can perform most of my daily activities without assistance.
- Group 1: Monotherapy
- Group 2: Combination Therapy
- Group 3: Standard of Care
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the common reasons that doctors prescribe Tremelimumab?
"While often used to treat advance directives, tremelimumab has also been found effective against fallopian tubes cancer, disease, and refractory testicular germ cell cancer."
Are there any dangers in using Tremelimumab?
"Tremelimumab has received a score of 3 for safety. This is because it has progressed to Phase 3 clinical trials, which suggests that not only is the medication effective, but also that there is significant data supporting its safety."
Could I possibly qualify to take part in this research project?
"Carcinoma patients that are non-small-cell lung cancer patients and between 18 and 130 years old can be accepted into this study. The clinical trial is enrolling around 1118 patients in total."
Are people currently being recruited to participate in this experiment?
"According to the latest update on clinicaltrials.gov, this particular trial is not currently looking for patients. The study was first posted on July 21st, 2015 but has not been updated since September 29th, 2022. There are 3482 other trials that are presently recruiting patients."
Does this research project have an age limit for participants?
"According to the study's requirements, patients must be aged 18-130 in order to participate. There are a total of 140 trials for people under 18 and 3408 for senior citizens."
Do we have any previous experience with Tremelimumab?
"Tremelimumab was first studied in 1997 at City of Hope Comprehensive Cancer Center. So far, there have been a total of 2761 completed clinical trials. As of now, 1923 clinical trials are actively recruiting with many of these taking place in Pembroke Pines, Florida."
In how many different countries is this research being conducted?
"Presently, the study is being conducted at 42 different sites. While Pembroke Pines, Honolulu and New york are a few of these locations, there are also other centres in close proximity. If you elect to participate in this clinical trial, it is best to choose a location that is convenient for you to reduce travel time and costs."
How many people have been recruited for this experiment?
"Unfortunately, this study is not currently recruiting patients. Although, it's important to note that the trial was last updated on September 29th, 2022 and was originally posted on July 21st, 2015. If you're interested in other studies, there are 1559 clinical trials for carcinoma, non-small-cell lung and 1923 Tremelimumab trials that are presently admitting patients."
What is the primary goal of this clinical trial?
"The primary objective of this study is to evaluate the progression-free survival (PFS) of patients treated with durvalumab and tremelimumab, compared to those receiving standard of care chemotherapy. Secondary objectives include determining the trough concentration (Ctrough_ss) of tremelimumab, PFS in the Fatel Association for cancer Research International biomarker population, and overall response rate (ORR) in the programmed cell death ligand 1 (PD-L1) analysis set population."
Share this study with friends
Copy Link
Messenger